Genetic influences on the response to warfarin
- 1 September 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 13 (5) , 357-361
- https://doi.org/10.1097/01.moh.0000239708.70792.4f
Abstract
Warfarin has a narrow therapeutic index and there is wide interindividual variability in the drug dose requirement. Uncertainty of response renders currently used loading regimens inaccurate as they fail to take into account individual patient factors that have a major influence on anticoagulation response. This review focuses on recent research findings demonstrating the impact of genetics on warfarin sensitivity and dose requirement and the issues concerning the clinical utility of individualized therapy. Single-nucleotide polymorphisms in cytochrome P450 2C9 and vitamin K epoxide reductase have been shown to make significant contributions to the variability in warfarin dose requirements. Polymorphisms in other genes that mediate the actions of warfarin make little or no contribution to the variability. Racial and cultural differences influence dose requirements, which can be explained at least in part by genetic and dietary factors. Individualization of therapy based on genetic and environmental factors has the potential to reduce the adverse effects associated with the commencement of warfarin therapy. Prospective studies that incorporate both CYP2C9 and VKORC1 genes and environmental factors in warfarin dose calculation will be required to demonstrate the safety, cost-effectiveness, and feasibility of individualized dosing regimens.Keywords
This publication has 37 references indexed in Scilit:
- Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populationsLife Sciences, 2005
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance doseThe Pharmacogenomics Journal, 2005
- Prospective dosing of warfarin based on cytochrome P-450 2C9 genotypeThrombosis and Haemostasis, 2005
- VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulationThrombosis and Haemostasis, 2005
- Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1Thrombosis and Haemostasis, 2005
- Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivityBlood, 2004
- Identification of the gene for vitamin K epoxide reductaseNature, 2004
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- Flexible induction dose regimen for warfarin and prediction of maintenance dose.BMJ, 1984